By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

NeuroDerm Ltd. 



Ofakim      Israel
Phone: 925-270-0519 Fax: 925-290-1209


SEARCH JOBS


Industry
Pharmaceutical






Company News
NeuroDerm (NDRM) To Host Fourth Quarter And 2016 Fiscal Year Financial Results Conference Call On March 30, 2017 3/21/2017 10:58:12 AM
NeuroDerm (NDRM) Achieves Primary Endpoint In ND0612H Phase II Trial For Advanced Parkinson’s Disease; Seeks Broader EU Label Based On Indigo Trial Following EMA Meeting 3/1/2017 11:28:18 AM
NeuroDerm (NDRM) Announces Extraordinary General Meeting Of Shareholders 1/27/2017 7:55:24 AM
NeuroDerm (NDRM) Announces Completion Of Patient Enrollment And Treatment In A Phase II Trial Of ND0612H For Advanced Parkinson’s Disease 12/22/2016 11:58:14 AM
NeuroDerm (NDRM) Announces Closing Of Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares 12/22/2016 9:00:48 AM
NeuroDerm (NDRM) Announces Closing Of A Follow-On Offering Of Ordinary Shares 12/7/2016 8:19:12 AM
NeuroDerm (NDRM) Announces Pricing Of A Follow-On Offering Of Ordinary Shares 12/7/2016 7:48:34 AM
NeuroDerm (NDRM) to Discontinue ND0612H Phase III, Suspend iNDiGO After FDA Meeting 12/5/2016 6:21:01 AM
NeuroDerm (NDRM) Announces Top-Line Results Of Pilot PK Trial Comparing ND0701 With Commercial Apomorphine 12/2/2016 7:18:18 AM
NeuroDerm (NDRM) Announces Third Quarter 2016 Financial Results 11/10/2016 9:01:32 AM
1234567
//-->